TECENTRIQ 1,875 mg (atezolizumab) - Metastatic non-small cell lung cancer (NSCLC)

Summary of opinion

Favourable opinion for reimbursement, only in the currently reimbursable indications of TECENTRIQ 840 mg, 1,200 mg (atezolizumab) concentrate for solution for infusion (I.V.):

• TECENTRIQ, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC. In patients with EGFR-mutant or ALK-positive NSCLC, TECENTRIQ, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies;
• TECENTRIQ as monotherapy is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumours have a PD-L1 expression ≥ 50% TC or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR-mutant or ALK-positive NSCLC;
• TECENTRIQ as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR-mutant or ALK-positive NSCLC should also have received targeted therapies before receiving TECENTRIQ;
• TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC);
• TECENTRIQ, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

No clinical added value of the new TECENTRIQ 1,875 mg (atezolizumab) solution for injection form compared to the solution for injection (IV) forms already available.